About AbOliGo
Pioneering high-performance antibody-oligonucleotide conjugates to unlock the power of multiomic analysis
Our Mission
"Our mission is to empower scientists by providing fast, reproducible, antibody-oligo conjugates (AOCs) for all."
AbOliGo is a biotechnology company developing next-generation antibody-oligonucleotide conjugates (AOCs) to unlock the power of multiomic analysis. Our proprietary conjugation platform delivers fast, reproducible, and customizable AOCs for spatial biology, proteomics, and single-cell workflows.
The Challenge: Despite over 7 million RUO antibodies available in the market, fewer than 0.1% are offered as AOCs, which will hinder scientific discovery.
AbOliGo is focused on solving this critical bottleneck through developing a conjugation platform which will deliver fast, reproducible, and customizable AOCs, transforming how researchers access these critical reagents. By enabling researchers to move seamlessly from antibody to multiomic insight, AbOliGo is redefining what's possible in biological discovery.
Technical and Commercial Execution
AbOliGo is deploying resources to achieve key milestones across innovation, manufacturing, and go-to-market efforts:
Miniaturized Process Development
Scaling down conjugation protocols to use as little as 10 µg of antibody input, allowing access to rare and costly antibodies.
Automated Manufacturing
Establishing an automated platform to increase throughput, precision, and reproducibility.
Commercial Expansion
Building a dedicated marketing and business development team to support the launch of the AOC platform.
Leadership
Brian Carpenter Ph.D.
CEO
Leading AbOliGo's mission to empower scientists with fast, reproducible antibody-oligo conjugates for all.
"We're removing the barriers that have kept high-quality AOCs out of reach for most researchers. Our platform makes it possible to go from any antibody to a conjugate in days, not weeks."
Nick Hutchings D.Phil.
Chairman
Founder of Absolute Antibody and Everest Biotech (both acquired by LSBio and now part of Vector Laboratories).
"AbOliGo is building a truly enabling technology platform. The company has the opportunity to reshape how researchers access high-quality AOCs at scale."
Mick Knowles
Head of Reagents
With over twenty years of conjugation expertise Mick is a named inventor on several conjugation patents (conjugation kits), and was the lead R&D scientist for Innova Biosciences.
"AbOliGo exists to remove the "black box" from antibody-oligo conjugation. In the reagent team we're re-engineering every step of the manufacturing process from oligo selection through to QC, allowing customers to have full confidence in our products."
Ed Ralph Ph.D.
CTO
Original member of the Abcam leadership team with deep experience spanning technology, marketing and life science.
"Since the days when I helped scale Abcam, technology has leaped ahead and we are now able to build slick, more functional, highly integrated systems more quickly and with less resource than ever before. Exciting times!"
Nick Gee Ph.D.
Non-Executive Director
Former CEO of Innova Biosciences and inventor of the Lightning-Link conjugation technology (acquired by Expedeon/SYGNIS and now sold by Abcam).
"Having scaled several reagent businesses, I can say AbOliGo is on a strong trajectory. We've engineered a solution that removes friction for both research and translational labs."
Karen Padgett MBA
Non-Executive Director
Founder & Former CEO at Novus Biologicals (acquired by Biotechne) and advisor to numerous biotech ventures.
"The combination of speed, reproducibility, and customizability is exactly what the market needs. I'm excited to help guide their commercial strategy."
Location
Headquartered in Cambridge, UK
Meditrina Building 260
Babraham Research Campus
Cambridge, CB22 3AT
Recent News
November 2025: AbOliGo announces the appointment of Dr. Ed Ralph as Chief Technology Officer. With a career spanning molecular biology, digital product leadership, and AI innovation, Dr. Ralph will lead the development of AbOliGo's AI-powered panel design platform.
Read the full announcement